anonymous
Guest
anonymous
Guest
In 2014, Lilly announced the following:
Sanofi is buying the rights to seek approval to sell Cialis over the counter in the United States, Europe, Canada and Australia after certain patents expire. Cialis is to lose its patent protection in the United States and Europe in 2017, after which sales are expected to drop sharply as cheaper generic alternatives arrive on the market.
Is Lilly still pursuing this strategy? Is there a plan to market Cialis OTC in the US this year?
Sanofi is buying the rights to seek approval to sell Cialis over the counter in the United States, Europe, Canada and Australia after certain patents expire. Cialis is to lose its patent protection in the United States and Europe in 2017, after which sales are expected to drop sharply as cheaper generic alternatives arrive on the market.
Is Lilly still pursuing this strategy? Is there a plan to market Cialis OTC in the US this year?